for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Anixa Biosciences Inc

ANIX.OQ

Latest Trade

3.87USD

Change

0.06(+1.57%)

Volume

8,782

Today's Range

3.77

 - 

3.88

52 Week Range

3.24

 - 

5.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.81
Open
3.84
Volume
8,782
3M AVG Volume
0.95
Today's High
3.88
Today's Low
3.77
52 Week High
5.70
52 Week Low
3.24
Shares Out (MIL)
20.21
Market Cap (MIL)
75.58
Forward P/E
-5.27
Dividend (Yield %)
--

Latest Developments

More

Anixa Biosciences Announces Collaboration with Urology Centers of Alabama

Anixa Biosciences says Co, Certain Current & Former Officers Entered Settlement Agreement With Co's Stockholder

Anixa Biosciences Inc Files For Mixed Shelf Of Up To $100 Million – SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Anixa Biosciences Inc

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing a cancer immunotherapy program, which leverages chimeric endocrine receptor t-cell (CER-T) technology, and is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek liquid biopsy technology is a series of non-invasive blood tests for early detection of solid tumors based on the body's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. This technology enables cancer detection in its earliest stages in efforts to treat patients when the disease is curable. The Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients.

Industry

Biotechnology & Drugs

Contact Info

3150 Almaden Expy Ste 250

+1.310.4845200

https://www.anixa.com/

Executive Leadership

Amit Kumar

Chairman of the Board, President, Chief Executive Officer

Michael J. Catelani

Chief Financial Officer, Chief Operating Officer, IR Contact Officer

Thomas Schlumpberger

Executive Vice President

Lewis H. Titterton

Lead Independent Director

David C. Cavalier

Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-0.760

2019(E)

-0.710
Price To Earnings (TTM)
--
Price To Sales (TTM)
302.30
Price To Book (MRQ)
13.00
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-249.06
Return on Equity (TTM)
-213.62

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up